LogicBio Therapeutics, Inc.

NasdaqGM:LOGC Stock Report

Market Cap: US$68.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LogicBio Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Key information

37.69%

Debt to equity ratio

US$5.93m

Debt

Interest coverage ration/a
CashUS$30.78m
EquityUS$15.74m
Total liabilitiesUS$22.86m
Total assetsUS$38.60m

Recent financial health updates

Recent updates

Seeking Alpha Oct 03

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

LogicBio (NASDAQ:LOGC) gained ~648% pre-market Monday after Alexion, a unit of AstraZeneca (NASDAQ:AZN) announced an agreement to acquire the U.S.-based genetic medicine company for $2.07 per share in cash. The Lexington, MA company boasts a genome editing platform, and an adeno-associated virus (AAV)-based gene delivery platform. "The proposed acquisition of LogicBio is a significant development for our growing research in genomic medicine,” remarked Marc Dunoyer, Chief Executive of Alexion, U.S.-based rare disease focused company that AZN acquired in 2021. Per the terms, an Alexion subsidiary will start a tender offer to acquire all outstanding shares of LOGC. Boards of both companies have approved the transaction which is expected to close in 4 – 6 weeks. The deal is likely to draw attention to gene editing companies such as CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), Editas Medicine (EDIT), Apellis Pharmaceuticals (APLS), and Verve Therapeutics (VERV) Gene therapy companies including bluebird bio (BLUE), uniQure N.V. (QURE), BioMarin Pharmaceutical (BMRN), Sarepta Therapeutics (SRPT), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA) are also likely to gain attention. Read about how U.S. biotech/ pharma stocks performed in Q3.
Analysis Article Aug 20

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Shareholders in LogicBio Therapeutics, Inc. ( NASDAQ:LOGC ) may be thrilled to learn that the analysts have just...
Analysis Article Aug 18

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

LogicBio Therapeutics, Inc. ( NASDAQ:LOGC ) just released its second-quarter report and things are looking bullish. The...
Seeking Alpha Aug 15

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

LogicBio press release (NASDAQ:LOGC): Q2 GAAP EPS of -$0.15. Revenue of $3.2M (+300.0% Y/Y). As of June 30, 2022, the company had cash and cash equivalents of $38.8M as compared to $53.5M as of Dec. 31, 2021
Analysis Article Jan 11

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Aug 18

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Apr 12

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Mar 08

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

If you want to know who really controls LogicBio Therapeutics, Inc. ( NASDAQ:LOGC ), then you'll have to look at the...
Analysis Article Jan 15

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

We believe investing is smart because history shows that stock markets go higher in the long term. But not every stock...

Financial Position Analysis

Short Term Liabilities: LOGC's short term assets ($32.8M) exceed its short term liabilities ($16.4M).

Long Term Liabilities: LOGC's short term assets ($32.8M) exceed its long term liabilities ($6.4M).


Debt to Equity History and Analysis

Debt Level: LOGC has more cash than its total debt.

Reducing Debt: Insufficient data to determine if LOGC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LOGC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LOGC has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 15.8% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/16 11:12
End of Day Share Price 2022/11/15 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LogicBio Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gbolahan Amusa BenzChardan Capital Markets, LLC
Silvan TuerkcanCitizens JMP Securities, LLC